(0.07%) 5 473.38 points
(0.11%) 39 153 points
(0.37%) 17 783 points
(0.15%) $80.95
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.25%) $28.94
(3.64%) $1 022.30
(0.29%) $0.936
(0.68%) $10.68
(0.44%) $0.792
(-0.28%) $87.24
Live Chart Being Loaded With Signals
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia...
Stats | |
---|---|
今日成交量 | 695 697 |
平均成交量 | 1.14M |
市值 | 3.79B |
EPS | $-0.520 ( Q4 | 2024-05-29 ) |
下一个收益日期 | ( $-0.520 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-13.80 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0650 (0.25%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-22 | Barnett Eva Renee | Sell | 4 042 | Common Stock |
2024-05-22 | Salzmann Peter | Sell | 16 163 | Common Stock |
2024-05-22 | Butchko Julia G. | Sell | 3 247 | Common Stock |
2024-05-22 | Macias William L. | Sell | 3 247 | Common Stock |
2024-05-22 | Levine Mark S. | Sell | 3 242 | Common Stock |
INSIDER POWER |
---|
85.45 |
Last 100 transactions |
Buy: 7 337 754 | Sell: 515 313 |
音量 相关性
Immunovant Inc 相关性 - 货币/商品
Immunovant Inc 财务报表
Annual | 2024 |
营收: | $0 |
毛利润: | $-231 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2024 |
营收: | $0 |
毛利润: | $-231 000 (0.00 %) |
EPS: | $-1.880 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.32M (0.00 %) |
EPS: | $-1.710 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.23M (0.00 %) |
EPS: | $-1.430 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。